UBS Maintains Buy on Perspective Therapeutics, Raises Price Target to $8

Benzinga Newsdesk www.benzinga.com Positive 76.9%

Neg 0% Neu 0% Pos 76.9%

UBS analyst David Dai maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the price target from $7 to $8.